Was the Solid Biosciences (SLDB) COO’s share sale a discretionary trade?

No, the transaction was not discretionary. The filing explicitly states the sale does not represent a discretionary trade by David T. Howton, but instead was executed under a durable automatic sale instruction to cover withholding taxes on vested restricted stock units.

What price range is disclosed for the Solid Biosciences (SLDB) share sales?

The shares were sold within a price range of $6.28 to $6.60. The weighted average sale price reported is $6.4419 per share, and the filing notes that detailed trade-level pricing information is available upon request from the reporting person.

Solid Biosciences (SLDB) COO sells 18,894 shares in automatic tax-withholding trade

Q: How many Solid Biosciences (SLDB) shares did the COO sell and at what price?

COO David T. Howton sold 18,894 SLDB shares of common stock at a weighted average price of $6.4419 per share . The filing notes these shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Solid Biosciences Chief Operating Officer sells shares to cover taxes. On February 4, 2026, COO David T. Howton sold 18,894 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.

The filing explains this was an automatic sale to cover withholding taxes after restricted stock units vested, under a pre-established durable automatic sale instruction. It states the transaction was not a discretionary trade. After this sale, Howton directly owned 97,859 shares of common stock.

Insider Trade Summary

Net Seller: 18,894 shares ($121,713)

Net Sell 1 txn

Insider Howton David T

Role Chief Operating Officer

Sold 18,894 shs ($122K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,894	$6.4419	$122K

Holdings After Transaction: Common Stock — 97,859 shares (Direct)

Footnotes (1)

This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/06/2026 - 06:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howton David T

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

02129

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/04/2026		S		18,894⁽¹⁾	D	$6.4419⁽²⁾	97,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

	/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Solid Biosciences (SLDB) disclose in this Form 4 filing?

Solid Biosciences reported an insider tax-related share sale. Chief Operating Officer David T. Howton sold 18,894 common shares on February 4, 2026 to cover withholding taxes after restricted stock units vested, under a pre-established automatic sale instruction.

How many Solid Biosciences (SLDB) shares did the COO sell and at what price?

COO David T. Howton sold 18,894 SLDB shares of common stock at a weighted average price of $6.4419 per share. The filing notes these shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive.

Why did the Solid Biosciences (SLDB) COO sell 18,894 shares?

The sale was made solely to cover tax withholding obligations. The filing states the shares were sold after previously granted restricted stock units vested, pursuant to a durable automatic sale instruction that effected a sell-to-cover election, rather than a discretionary trade.

How many Solid Biosciences (SLDB) shares does the COO own after this transaction?

After the tax-related sale, the COO directly owns 97,859 shares. The Form 4 shows that following the reported sale of 18,894 common shares, David T. Howton’s directly held beneficial ownership stands at 97,859 shares of Solid Biosciences common stock.